Table 1.
Clinical trials of immune checkpoint inhibitors in B-cell non-Hodgkin lymphoma.
| Trial ID (Name) | Authors | Year | Intervention(s) | Phase | Disease(s) | N | CR | OR | PFS |
|---|---|---|---|---|---|---|---|---|---|
| NCT00089076 | Ansell et al. | 2009 | Ipilimumab | I | FL DLBCL MCL |
14 3 1 |
0% 33% 0% |
7% 33% 0% |
N.A. |
| NCT00904722 | Westin et al. | 2014 | Pidilizumab + Rituximab | II | FL | 29 | 52% | 66% | N.A. |
|
NCT01592370 (CHECKMATE-039) |
Ansell et al. | 2016 | Nivolumab + Ipilimumab | Ib | B-NHL | 15 | 0% | 20% | median 1.5 months |
|
NCT01592370 (CHECKMATE-039) |
Lesokhin et al. | 2016 | Nivolumab | Ib | FL DLBCL Other B-NHL |
10 11 10 |
10% 18% 0% |
40% 36% 0% |
median 23 weeks |
| - | Nayak et al. | 2017 | Nivolumab | I | PCNSL PTL |
4 1 |
75% 100% |
100% 100% |
N.A |
|
NCT01953692 (KEYNOTE-013) |
Zinzani et al. | 2017 | Pembrolizumab | Ib | PMBCL | 17 | 12% | 41% | N.A. |
| NCT02220842 | Palomba et al. | 2017 | Atezolizumab + Obinutuzumab | Ib | FL DLBCL |
26 23 |
N.A. N.A. |
57% 16% |
N.A. |
| NCT02332980 | Ding et al. | 2017 | Pembrolizumab | II | CLL CLL with RT |
16 9 |
0% 11% |
0% 44% |
median 2.4 months median 5.4 months |
| NCT02446457 | Nastoupil et al. | 2017 | Pembrolizumab + Rituximab | II | FL | 25 | 60% | 80% | N.A. |
| NCT02596971 | Younes et al. | 2017 | Atezolizumab + Obinutuzumab + Bendamustine | Ib/II | untreated FL | 15 | 67% | 80% | N.A. |
| NCT02596971 | Younes et al. | 2018 | Atezolizumab + R-CHOP | I/II | untreated DLBCL | 40 | 78% | 88% | N.A. |
| NCT01729806 | Tuscano et al. | 2019 | Ipilimumab + Rituximab | I | FL Other B-NHL |
13 20 |
15% 0% |
38% 3% |
median 2.6 months |
|
NCT01953692 (KEYNOTE-013) |
Armand et al. | 2019 | Pembrolizumab | Ib | PMBCL | 21 | 33% | 48% | median 10.4 months |
|
NCT02038933 (CHECKMATE-139) |
Ansell et al. | 2019 | Nivolumab | II | DLBCL s/p failed auto-HSCT DLBCL ineligible for auto-HSCT |
87 34 |
3% 0% |
10% 3% |
median 1.9 months median 1.4 months |
| NCT02329847 | Younes et al. | 2019 | Nivolumab + Ibrutinib | I/II | CLL/SLL FL DLBCL CLL with RT |
36 40 45 20 |
0% 10% 16% 10% |
61% 33% 36% 65% |
N.A. median 9.1 months median 2.6 months median 5.0 months |
|
NCT02576990 (KEYNOTE-170) |
Armand et al. | 2019 | Pembrolizumab | II | PMBCL | 53 | 13% | 45% | median 5.5 months |
|
NCT02581631 (CHECKMATE-436) |
Zinzani et al. | 2019 | Nivolumab + BV | I/II | PMBCL | 30 | 37% | 73% | 63.5% at 6 months |
|
NCT02733042 (FUSION NHL-001) |
Casulo et al. | 2019 | DurvalumabDurvalumab + Lenalidomide ± RituximabDurvalumab + Rituximab ± Bendamustine | I/II | DLBCL FL |
38 22 |
8% 27% |
18% 59% |
median 2.5 months median 10.6 months |
| - | Smith et al. | 2020 | Pembrolizumab + R-CHOP | II | untreated DLBCL untreated FL |
27 3 |
77% | 90% | 83% at 24 months |
| NCT02401048 | Herrera et al. | 2020 | Durvalumab + Ibrutinib | Ib/II | FL DLBCL (GC) DLBCL (non-GC) |
27 16 16 |
4% 6% 31% |
26% 13% 38% |
median 10.2 months median 2.9 months median 4.1 months |
|
NCT02038946 (CHECKMATE-140) |
Armand et al. | 2021 | Nivolumab | II | FL | 92 | 1% | 4% | median 2.2 months |
All disease groups are relapsed/refractory unless otherwise specified. Abbreviations: N, number of patients; CR, complete response, OR, overall response; PFS, progression free survival; N.A., not assessed; s/p, status post; GC, germinal center; RT, Richter transformation.